timothy sykes logo

Stock News

Veracyte Stock Soars Amid Revenue and EPS Surprises

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Matt Monaco Fact-checked by Bryce Tuohey
Updated 11/22/2025, 11:21 am ET 11/22/2025, 11:21 am ET | 4 min 4 min read
Veracyte Stock Soars Amid Revenue and EPS Surprises Thumbnail

Veracyte Inc.’s stocks have been trading up by 9.89 percent, driven by positive market sentiment and promising financial outlook.

Healthcare industry expert:

Analyst sentiment – positive

  1. Veracyte, Inc. (VCYT) exhibits financial robustness in certain key metrics despite exhibiting some profitability challenges. The company boasts a healthy gross margin of 68.5%, indicative of strong core operations. However, profitability remains an area of concern, as seen by a pre-tax profit margin of -8.6%. Additionally, VCYT demonstrates considerable valuation ratios with a P/E ratio at 104.74, possibly showcasing overvaluation relative to net earnings. Notably, the financial strength is evident with a current ratio of 6.2 and a low total debt to equity ratio at 0.03, underscoring robust liquidity and prudent leverage management.

  2. Technically, Veracyte’s weekly price pattern shows a conspicuous upward trajectory, closing at $44.89 after starting at $39.28. This consistent climb illustrates bullish sentiment, intensified by strong volume on price spikes, indicating sustained interest and momentum. The dominant trend is upward, reinforced by recent price surges. A strategic entry is suggested above $45.00, targeting a breakout, with a stop-loss limiting risk at $43.00. The focus should be on volume staying above the norm to confirm breakout validity.

  3. Recent catalysts, including impressive earnings results surpassing consensus estimates, upward revisions of fiscal year revenue forecasts, and enhanced guidance, bolster Veracyte’s outlook. The inclusion of the Decipher test in revised NCCN guidelines provides a strategic advantage within cancer diagnostics. Sector performance comparison shows Veracyte outpacing Healthcare and Medical Diagnostics benchmarks. With UBS increasing the price target to $48 and supported by strengthened fundamentals, Veracyte’s prospects look promising. Trading strategies should consider key levels: immediate support at $44.00 and resistance at $48.00; a breach of the latter could signal continued strength towards a projected target.

Candlestick Chart

Weekly Update Nov 17 – Nov 21, 2025: On Saturday, November 22, 2025 Veracyte Inc. stock [NASDAQ: VCYT] is trending up by 9.89%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Veracyte is experiencing a notable rise in stock price, reflecting robust third-quarter performance. The company not only exceeded analysts’ earnings per share expectations but also reported revenue figures significantly above forecasted numbers. The Q3 revenue reached an impressive $131.9M, while the anticipated figure was set at $124.85M, underscoring the firm’s effective strategies in addressing market demands. This success allowed the company to revise its FY25 revenue forecast upwards to a range of $506M to $510M, further boosting investor confidence.

Profitability metrics reveal an EBIT margin of 6.3% and an EBITDA margin of 10.8%, illustrating the ability to convert higher revenues into earnings effectively. The company’s solid cash flow, evident from an increase of $95.99M, provides a strong foundation for reinvestment into strategic growth initiatives. Additionally, ratios such as a gross margin of 68.5% emphasize operational efficiency. With a P/E ratio standing at 104.74, investors are evidently optimistic about future earnings growth.

The market’s positive reception can be tied to these financial gains alongside strategic decisions such as continual participation in investor conferences and effectively communicated future guidance. Analyst upgrades and positive changes in NCCN guidelines only serve to heighten this sentiment further. Consequently, with asset leverage ratios and current ratios reflecting strong financial health, Veracyte is positioned for potential growth.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”